

## MEDICATION MANAGEMENT FOR THE OLDER ADULT

Jessica Starr

DISCUSSES THE ROLE OF ORAL ANTICOAGULATION IN PATIENTS WITH  
STAGE 5 OR END STAGE KIDNEY DISEASE

Recorded Webinar



## PROGRAM OVERVIEW

Oral anticoagulation (OAC) is the mainstay of therapy for atrial fibrillation (AF) and venous thromboembolism (VTE). For decades, vitamin K antagonists (VKA) have been the standard of care for these patients. With the rapid adoption of direct-acting oral anticoagulants (DOACs), major guidelines now give preference to these agents over VKAs in a variety of patients. Presently, patients with stage 5 chronic kidney disease (CKD-5) or end-stage kidney disease (ESKD), with an indication for OAC, have only been studied in one small randomized trial. All DOACs currently marketed in the US with labelling for AF and VTE are eliminated to some degree renally as unchanged drug. Renal elimination is greatest with dabigatran (80%) and edoxaban (50%) and less with rivaroxaban (33%) and apixaban (27%). Small, single-dose pharmacokinetic studies support the dosing recommendations in the product labelling for apixaban and rivaroxaban. Further, the management of these patients is complicated by a higher risk of bleeding compared to the normal population. Despite this, the use of DOACs in patients with CKD has increased. Specifically, in patients with CKD and nonvalvular AF, the overall use of OAC increased from 56.8% in 2009 to 66.3% in 2018. There has also been decrease in the use of warfarin and an increase use of DOACs. In 2013, DOACs were prescribed to 10.7% of patients with CKD compared 45.1% prescribed warfarin. Data from 2018 shows an increase in DOAC use (38.7%) and decrease in warfarin use (24.5%). Specifically, in the stage 4 or 5 CKD patients on OAC, 2018 shows 33.3% receiving a DOAC and 27.1% receiving warfarin.

This program will provide 1 hour of CE credit and is offered as a recorded webinar. Following registration, participants will have access to course instructions, updates, presentations, webinar link, program evaluation, CE certificates and credits, etc. **This program is approved for 1 ACPE Contact Hours, .1 CEUs.** Once credit is awarded, transcripts will be available online within 24 hours on the learner's CPE Monitor profile at [www.nabp.net](http://www.nabp.net). **This program is also approved by the Alabama Board of Pharmacy.**

*The Office of Post Graduate Education strongly encourages each participant to check their profile online within 60 days of attendance to ensure credit has been awarded properly. ACPE will not accept CE submissions after 60 days from the live seminar date.*

This program is not sponsored by an external organization.

## TARGET AUDIENCE

This knowledge-based program is intended for Pharmacists

## FACULTY DISCLOSURES

Programming in with AUHSOP is in any way involved, whether as sole provider or joint-providership, shall exhibit fair content balance, providing the audience with information of multiple perspectives from which to form a professional opinion. In addition, the fair balance will assure that information provided does not discuss a commercial product. Brand names of all products included in the content may be mentioned for identification purposes only. Presenters in any continuing education offering will acknowledge and disclose any affiliation with the provider and such information will be made available to the audience.

Faculty disclosures will also be included on an introductory slide during the presentation. All listed faculty have no actual or potential conflict of interest in relation to this program.

## FACULTY

Jessica Starr, PharmD, FCCP, BCPS is an Associate Clinical Professor in the Department of Pharmacy Practice at the Harrison School of Pharmacy. Originally from Pensacola, Florida, Dr. Starr completed her pre-pharmacy coursework at the University of California, Santa Barbara and graduated with her Doctor of Pharmacy from the Harrison School of Pharmacy. After graduation, she moved to Charleston, South Carolina where she completed an ASHP-accredited pharmacy practice residency and a specialty residency in adult internal medicine at the Medical University of South Carolina.

Dr. Starr is extensively involved in curricular design for the practice ready curriculum where she serves as the course coordinator for the P3 fall semester. She has developed and currently executes the evidenced-based medicine course work which is integrated throughout the first three professional years. Her primary area of expertise is cardiovascular pharmacotherapy where she has both mapped and extensively taught these disease states during the P1, P2, and P3 years. She also offers both an IPPE and APPE clinical rotation in Internal Medicine at her practice site, Princeton Baptist Medical Center.

Dr. Starr has received numerous awards while at the Harrison School of Pharmacy. She was awarded the Lucinda Maine Fellow in Teaching which recognizes a faculty member who has excelled in the effort to create a powerful and inspiring learning environment that establishes the school as the leading destination for outstanding Doctor of Pharmacy and Graduate Students.

## FACULTY Cont'd

Dr. Starr also received the school's inaugural Excellence in Outreach award for her work at Princeton Baptist Medical Center. She has been recognized as a Preceptor of Excellence numerous times and has received the Rho Chi Distinguished Alumni Award.

Dr. Starr is extensively involved in both the American Society of Health-System Pharmacists (ASHP) and the American College of Clinical Pharmacy (ACCP) where she has served on a variety of committees and held numerous leadership roles. Most notably she is a past chair of the Adult Medicine PRN for ACCP and was recognized as a fellow in this organization in 2014.

## ACCREDITATION INFORMATION



The Auburn University Harrison School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education; credits are recognized nationwide. The Universal Activity Number for this knowledge-based program is 0001-0000-21-019-H04-P and is intended for pharmacists only. The initial release date for this home-study program is September 16, 2021, and the intended expiration is September 16, 2024.

This program is approved by the Alabama Board of Pharmacy for **Consultant** update hours. A monthly report of completions is sent to the AIBOP for enduring online programs.

## ACTIVITY COMPLETION REQUIREMENTS

To complete the steps for CE credit, each attendee will be required to access and review program materials located within the online course, watch the recorded webinar, finish the program evaluation within the online course, and claim credit within the course. Please contact [hsopce@auburn.edu](mailto:hsopce@auburn.edu) if you have any questions or needs related to this online CE program.

# POST-GRADUATE EDUCATION ADVISORY COMMITTEE

Spencer Durham, Pharm.D., BCPS, BCIDP  
Associate Clinical Professor, Director of Alumni & Professional Affairs

Angela Calderon, Ph.D.  
Associate Professor, Drug Discovery and Development

Sarah Cogle, Pharm.D., BCCCP  
Assistant Clinical Professor, Pharmacy Practice

Danielle Waites, MSW  
Patient Care Coordinator, Clinical Affairs and Outreach

Edward Chou, Ph.D.  
Associate Professor  
Department: Health Outcomes Research and Policy

Haley Phillippe, Pharm.D., BCPS, BCGP, FASCP  
Associate Clinical Professor, Pharmacy Practice

Erika Kleppinger, Pharm.D., BCPS  
Associate Clinical Professor, Pharmacy Practice

Alison Baker, Pharm.D.  
Coordinator of Distributive Services, AU Employee Pharmacy

Marian Williams, MS  
Academic Programs Administrator, Faculty Affairs and Strategic Initiatives

Tanja Redd, MBA  
Academic Programs Coordinator, Alumni and Professional Affairs

Brianna Foster  
Academic Programs Administrator, Clinical Affairs and Outreach

*Members of the Post-Graduate Education Advisory Committee have completed a conflict-of-interest disclosure form and have no actual or potential conflicts of interest in relation to this program.*